Assembly Biosciences (ASMB) Current Deferred Revenue (2017 - 2026)

Assembly Biosciences' Current Deferred Revenue history runs 10 years deep, the most recent figure standing at $29.1 million for Q1 2026.

• On a quarterly basis, Current Deferred Revenue fell 28.77% year-over-year to $29.1 million in Q1 2026; TTM through Mar 2026 was $29.1 million, a 28.77% decrease from a year earlier, with the FY2025 full-year figure at $36.9 million, down 1.91% from the prior year.
• Current Deferred Revenue eased to $29.1 million in Q1 2026 per ASMB's latest filing, from $36.9 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $86.3 million in Q4 2023 and bottomed at $2.7 million in Q4 2022.
• The 5-year median for Current Deferred Revenue is $40.8 million (2025), against an average of $45.6 million.
• Across the five-year window, Current Deferred Revenue soared 3057.48% in 2023 and tumbled 56.4% in 2024, its largest moves.
• Year by year, Current Deferred Revenue stood at $2.7 million in 2022, then surged by 3057.48% to $86.3 million in 2023, then tumbled by 56.4% to $37.6 million in 2024, then declined by 1.91% to $36.9 million in 2025, then fell by 21.21% to $29.1 million in 2026.
• Per Business Quant, the three latest ASMB Current Deferred Revenue figures stand at $29.1 million (Q1 2026), $36.9 million (Q4 2025), and $42.4 million (Q3 2025).